Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

NCT04843774 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT04843774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04843774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)
Lead sponsor
NYU Langone Health
Phase
Observational
Overall status
Completed
Start date
April 20, 2021
Completion date
April 18, 2023
Enrollment
64 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis